Lamotrygina, znana r\u00f3wnie\u017c jako Lamictal, to lek przeciwpadaczkowy, kt\u00f3ry by\u0142 zatwierdzone przez FDA<\/a> for treatment of epilepsy and bipolar disorder. Lamotrigine is used alone or with other medicines to treat seizures in patients two years and older. It may also be used as maintenance treatment in patients with bipolar disorder to help delay the occurrence of mood episodes such as depression, mania, or hypomania. Stopping lamotrigine without first talking to a prescriber can lead to uncontrolled seizures, or new or worsening mental health problems. Lamotrigine has been approved and on the market for 24 years, and is available under the brand name Lamictal and as generics.<\/p>\n Lamictal was first sold in the United States in 1994 and is manufactured by GlaxoSmithKline. It is a sodium channel blocker that helps by suppressing the excitatory neurotransmitters in the central nervous system.\u00a0 Lamictal is available both as an oral tablet and in a chewable form and is metabolized by the liver.\u00a0 Between 2005 and 2015, there were more than 900,000,000 prescriptions for the drug in the United States.\u00a0\u00a0 Lamictal has been one of GlaxoSmithKline\u2019s best-selling drugs of all time and sales between March 2007 and March 2008 exceeded $2 billion.<\/p>\n <\/p>\n Opr\u00f3cz pomocy przy zaburzeniach nastroju pacjent\u00f3w, Lamictal by\u0142 r\u00f3wnie\u017c dopuszczony do u\u017cytku<\/a> jako lek przeciwpadaczkowy.<\/p>\n Artyku\u0142 napisany w 2008 roku<\/a> by Nasser et al. reviewed evidence from Lamictal trials that were unpublished, and it concludes that lamotrigine has “very limited, if any, efficacy in the treatment of acute bipolar depression”. A Artyku\u0142 z 2008 r. autorstwa Calabrese i in.<\/a> przeanalizowali wi\u0119kszo\u015b\u0107 tych samych danych i stwierdzili, \u017ce w pi\u0119ciu badaniach kontrolowanych placebo lamotrygina nie r\u00f3\u017cni\u0142a si\u0119 istotnie od placebo w leczeniu depresji w przebiegu choroby afektywnej dwubiegunowej.<\/p>\n <\/p>\n Jako efekt uboczny stosowania leku Lamictal zidentyfikowano bardzo powa\u017cn\u0105 i zagra\u017caj\u0105c\u0105 \u017cyciu reakcj\u0119 uk\u0142adu odporno\u015bciowego. Ta reakcja uk\u0142adu odporno\u015bciowego nazywana jest HLH (co oznacza limfohistiocytoz\u0119 hemofagocytarn\u0105), kt\u00f3ra powoduje, \u017ce uk\u0142ad odporno\u015bciowy uszkadza tkanki i narz\u0105dy organizmu. Mo\u017ce to powodowa\u0107 ci\u0119\u017ckie stany zapalne w ca\u0142ym ciele i prowadzi\u0107 do hospitalizacji i \u015bmierci, zw\u0142aszcza je\u015bli reakcja nie zostanie szybko zdiagnozowana i leczona. HLH zwykle objawia si\u0119 uporczyw\u0105 gor\u0105czk\u0105, zwykle wy\u017csz\u0105 ni\u017c 101\u00b0F, i mo\u017ce prowadzi\u0107 do powa\u017cnych problem\u00f3w z krwinkami i narz\u0105dami w ca\u0142ym ciele, takimi jak w\u0105troba, nerki, m\u00f3zg i p\u0142uca.<\/p>\n <\/p>\n Wed\u0142ug Food and Drug Administration, diagnoz\u0119 HLH mo\u017cna ustali\u0107, je\u015bli pacjent ma co najmniej pi\u0119\u0107 z nast\u0119puj\u0105cych o\u015bmiu objaw\u00f3w:<\/p>\n Pacjenci lub ich opiekunowie powinni natychmiast skontaktowa\u0107 si\u0119 z pracownikami s\u0142u\u017cby zdrowia, je\u015bli podczas przyjmowania lamotryginy wyst\u0105pi\u0105 jakiekolwiek objawy HLH. HLH mo\u017ce wyst\u0105pi\u0107 w ci\u0105gu kilku dni lub tygodni po rozpocz\u0119ciu leczenia. Badanie fizykalne i okre\u015blone laboratoryjne badania krwi oraz inne oceny s\u0105 wykorzystywane do diagnozowania HLH. Oznaki i objawy HLH obejmuj\u0105 mi\u0119dzy innymi:<\/p>\n <\/p>\n <\/p>\n W dniu 25 kwietnia 2018 r. o godz FDA wyda\u0142a ostrze\u017cenie<\/a> that Lamictal can cause this rare, but very serious reaction.\u00a0Because of the association with HLH, the FDA required the manufacturer of Lamictal to add a new warning about the risk of HLH to the prescribing information in the lamotrigine drug labels. \u00a0The FDA also issued an alert to healthcare professionals stating they should be aware that prompt recognition and early treatment is important for improving HLH outcomes and decreasing mortality. Diagnosis is often complicated because early signs and symptoms such as fever and rash are not specific. HLH may also be confused with other serious immune-related adverse reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).<\/p>\n In the 24 years since lamotrigine\u2019s 1994 approval, the FDA identified many cases worldwide of confirmed or suspected HLH associated with the medicine in children and adults. This number includes only reports submitted to FDA and found in the medical literature, so there are likely additional cases about which the FDA is unaware. The FDA determined that \u201cthere was reasonable evidence that lamotrigine was the cause of HLH\u201d in these cases based on the timing of events and the order in which they occurred. The patients in these cases required hospitalization and received drug and other medical treatments, with one patient dying.<\/p>\n <\/p>\n Lamictal zrani\u0142 tysi\u0105ce ludzi, kt\u00f3rzy nie mieli poj\u0119cia, \u017ce lek jest niebezpieczny. Je\u015bli u Ciebie lub u kogo\u015b bliskiego zdiagnozowano HLH podczas przyjmowania Lamictal, skontaktuj si\u0119 z Napoli Shkolnik PLLC i porozmawiaj z do\u015bwiadczonym adwokat w sprawach farmaceutycznych<\/a> w Nowym Jorku. Nie pobieramy z g\u00f3ry op\u0142at prawnych w sprawach dotycz\u0105cych zaniedba\u0144.<\/p>","protected":false},"excerpt":{"rendered":" WE ARE NO LONGER ACCEPTING LAMICTAL CASES Background Lamotrigine, also known as Lamictal, is an anti-seizure medication that was approved by the FDA for treatment of epilepsy and bipolar disorder….<\/p>","protected":false},"featured_media":0,"menu_order":137,"template":"","practiceareas_category":[743],"class_list":["post-5934","practiceareas","type-practiceareas","status-publish","hentry","practiceareas_category-pharmaceutical-litigation"],"acf":[],"_links":{"self":[{"href":"https:\/\/napolilaw.lemonadestand.org\/pl\/wp-json\/wp\/v2\/practiceareas\/5934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/napolilaw.lemonadestand.org\/pl\/wp-json\/wp\/v2\/practiceareas"}],"about":[{"href":"https:\/\/napolilaw.lemonadestand.org\/pl\/wp-json\/wp\/v2\/types\/practiceareas"}],"version-history":[{"count":0,"href":"https:\/\/napolilaw.lemonadestand.org\/pl\/wp-json\/wp\/v2\/practiceareas\/5934\/revisions"}],"wp:attachment":[{"href":"https:\/\/napolilaw.lemonadestand.org\/pl\/wp-json\/wp\/v2\/media?parent=5934"}],"wp:term":[{"taxonomy":"practiceareas_category","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/pl\/wp-json\/wp\/v2\/practiceareas_category?post=5934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Lamictal jako lek przeciwpadaczkowy<\/h3>\n
Lamictal i HLH<\/h3>\n
Informacje o HLH<\/h2>\n
\n
\n
Fakty dotycz\u0105ce Lamotryginy (Lamictal)<\/h2>\n
\n
\n
Akcja FDA na rzecz bezpiecze\u0144stwa<\/h3>\n
Porozmawiaj z prawnikiem<\/h3>\n